Vanguard Asset Management
PVLA

Vanguard Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Vanguard Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$978K Hold
6,399
– – ﹤0.01% 1881
2026
Q1 		$798K Buy
+6,399
New +$667K ﹤0.01% 1889

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Asset Management's PVLA Position: Q2 2026 in Review

Vanguard Asset Management held its Palvella Therapeutics (PVLA) position steady in Q2 2026 at 6,399 shares worth $978K. The position accounts for ﹤0.01% of the portfolio, ranked #1881.

Vanguard Asset Management first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 181 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Vanguard Asset Management held 6,399 shares of Palvella Therapeutics worth $978K as of Q2 2026.
  • Vanguard Asset Management left its Palvella Therapeutics share count unchanged in Q2 2026.
  • Palvella Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #1881 holding.
  • Vanguard Asset Management first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 181 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.